ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1/2 study.

29-May-2024 9:05 PM EDT, by Yale Cancer Center/Smilow Cancer Hospital contact patient services

For this presentation at ASCO 2024, please email the media contact for more information.

Research Alert

MEDICINE

0.38182